The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test. The platform reveals vital information about a pregnancy's unique biology by analyzing tens of thousands of RNA messages that drive dramatic changes throughout pregnancy. 1,2,3
It starts in 2018, with a pilot study from Dr. Stephen Quake’s lab in Stanford. It showed RNA profiles accurately classified women who delivered preterm up to 2 months in advance using a simple blood sample.
That pilot study led to the founding of Mirvie. We quickly set out to validate those initial learnings in preterm birth to preeclampsia in a diverse, large, and global collaborative study.
Predicts 75% of preeclampsia cases months in advance
The results showed the platform creates a molecular clock for normal pregnancy development that is able to predict gestational age as well as, or better than a 2nd trimester ultrasound. When applied to preeclampsia, the platform had a 75% detection rate months in advance.
Building on our results in Nature, or focus returned to understanding the underlying biological drivers of preterm birth. Here we saw the platform can predict 76% of early preterm birth because of RNA messages related to premature changes to the cervix for cases less than 35 weeks.
Predicts 76% of early preterm birth 2 months in advance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
